#1 Clinical Trials Search in Europe

Ripretinib

Ripretinib is an innovative drug being studied in clinical trials for the treatment of advanced gastrointestinal stromal tumors (GIST). This article explores the ongoing research on ripretinib, its potential benefits, and its role in improving outcomes for patients with GIST who have progressed on prior therapies.

Table of Contents

What is Ripretinib?

Ripretinib, also known by its brand name QINLOCK or research code DCC-2618, is an oral medication used to treat advanced gastrointestinal stromal tumors (GIST)[1]. GIST is a type of cancer that starts in special cells in the wall of the digestive system, called interstitial cells of Cajal. These tumors can occur anywhere along the digestive tract but are most common in the stomach and small intestine.

Ripretinib is classified as a kinase inhibitor, which means it works by blocking specific proteins (kinases) that are involved in the growth and spread of cancer cells[2]. It is typically used in patients who have already tried other treatments, such as imatinib, and whose cancer has continued to grow or spread.

How Ripretinib Works

Ripretinib is known as a switch-control tyrosine kinase inhibitor[3]. To understand how it works, it’s helpful to know that many GISTs have mutations in genes called KIT or PDGFRA. These mutations cause the cancer cells to grow and divide uncontrollably. Ripretinib works by targeting and blocking these mutated proteins, which can help slow down or stop the growth of the tumor.

What makes ripretinib unique is its ability to target multiple forms of these mutated proteins, including forms that have become resistant to other treatments. This is why it can be effective in patients whose cancer has progressed after trying other medications[4].

Conditions Treated by Ripretinib

Ripretinib is primarily used to treat advanced gastrointestinal stromal tumors (GIST). Specifically, it is approved for use in patients who have received prior treatment with at least three kinase inhibitors, including imatinib[5]. This means it’s typically used as a fourth-line or later treatment option.

Research is ongoing to determine if ripretinib could be effective earlier in the treatment process. For example, some studies are looking at its use as a second-line treatment after imatinib[4].

Efficacy and Safety of Ripretinib

Clinical trials have shown promising results for ripretinib in treating advanced GIST. Key measures of its effectiveness include:

  • Progression-Free Survival (PFS): This measures how long patients live without their cancer getting worse. Studies have shown that ripretinib can significantly improve PFS compared to other treatments[1].
  • Objective Response Rate (ORR): This measures the percentage of patients whose tumors shrink or disappear with treatment. Ripretinib has shown favorable ORR in clinical trials[1].
  • Overall Survival (OS): This measures how long patients live after starting treatment. Studies are ongoing to determine the long-term survival benefits of ripretinib[1].

In terms of safety, ripretinib has been generally well-tolerated in clinical trials. However, like all medications, it can cause side effects, which we’ll discuss in a later section.

How Ripretinib is Administered

Ripretinib is taken orally, usually as tablets. The typical dose is 150 mg once daily, but this can vary depending on individual patient factors[3]. It’s important to take ripretinib exactly as prescribed by your doctor.

Treatment is usually given in cycles, with each cycle lasting 28 days (4 weeks). Patients typically continue taking ripretinib until their disease progresses or they experience unacceptable side effects[6].

Potential Side Effects

While ripretinib is generally well-tolerated, it can cause side effects. Common side effects may include:

  • Fatigue
  • Nausea
  • Abdominal pain
  • Constipation
  • Muscle pain
  • Hair loss
  • Hand-foot syndrome (redness, swelling, and pain on the palms of hands and soles of feet)

More serious side effects can occur but are less common. These may include skin reactions, high blood pressure, and heart problems. It’s important to report any side effects to your healthcare team promptly[7].

Ongoing Research and Future Directions

Research on ripretinib is ongoing, with several clinical trials currently in progress. These studies are exploring various aspects of the drug, including:

  • Its use in earlier stages of GIST treatment[4]
  • Combination therapy with other drugs[6]
  • Its effectiveness in specific genetic subtypes of GIST[4]
  • Long-term safety and efficacy data[8]

These ongoing studies aim to further improve treatment outcomes for patients with GIST and potentially expand the use of ripretinib to benefit more patients.

Aspect Details
Drug Name Ripretinib (also known as DCC-2618, QINLOCK)
Type of Drug Oral KIT/PDGFRA kinase inhibitor
Primary Indication Advanced Gastrointestinal Stromal Tumors (GIST)
Key Clinical Trials Phase 1b/2, Phase 3 studies comparing to sunitinib
Main Outcomes Measured Progression-Free Survival (PFS), Objective Response Rate (ORR), Overall Survival (OS)
Dosing Typically 150 mg once daily in continuous 28-day or 42-day cycles
Patient Population GIST patients who have progressed on or are intolerant to prior therapies, including imatinib
Combination Studies Being evaluated in combination with binimetinib and other anticancer therapies
Safety Assessments Monitoring of adverse events, dose modifications, and pharmacokinetics
Quality of Life Measures EQ-5D-5L questionnaire used in some studies to assess patient well-being

FAQ

  • What is ripretinib? Ripretinib is an oral kinase inhibitor that targets specific mutations in GIST. It is designed to treat patients with advanced GIST who have progressed on or are intolerant to prior therapies.
  • How is ripretinib being studied in clinical trials? Ripretinib is being studied in various clinical trials, including comparisons with other drugs like sunitinib, combination studies with other medications, and evaluations of its effectiveness in different lines of therapy for GIST patients.
  • What are the main goals of ripretinib clinical trials? The main goals include assessing the safety and efficacy of ripretinib, determining the appropriate dosing, evaluating progression-free survival, and measuring objective response rates in GIST patients.
  • Are there any side effects associated with ripretinib? As with any medication, ripretinib may have side effects. Clinical trials are designed to monitor and assess the safety profile of the drug, including any adverse events that may occur during treatment.
  • How long do ripretinib clinical trials typically last? The duration of ripretinib clinical trials varies, but many studies last between 12 to 36 months, with some extending up to 48 months for long-term follow-up on overall survival.

Ongoing Clinical Trials on Ripretinib

  • Study of DCC-3116 and ripretinib combination therapy in patients with advanced gastrointestinal stromal tumor (GIST)

    Recruiting

    1 1 1 1
    Investigated diseases:
    Investigated drugs:
    Denmark France Germany Greece Italy The Netherlands +2

  • Study Comparing Ripretinib and Sunitinib for Patients with Advanced Gastrointestinal Stromal Tumors Previously Treated with Imatinib

    Not recruiting

    3 1 1 1
    Investigated diseases:
    Investigated drugs:
    France Italy The Netherlands Norway Spain

  • Study of Ripretinib vs Sunitinib for Patients with Advanced Gastrointestinal Stromal Tumor with Specific KIT Exon Mutations Previously Treated with Imatinib

    Not recruiting

    3 1 1 1
    Investigated diseases:
    Investigated drugs:
    France Germany Hungary Italy The Netherlands Norway +2

Glossary

  • Gastrointestinal Stromal Tumor (GIST): A type of cancer that occurs in the digestive tract, most commonly in the stomach or small intestine.
  • Kinase inhibitor: A type of drug that blocks specific enzymes called kinases, which are involved in cell signaling and growth.
  • Progression-Free Survival (PFS): The length of time during and after treatment that a patient lives with the disease without it worsening.
  • Objective Response Rate (ORR): The proportion of patients whose cancer shrinks or disappears after treatment.
  • Disease Control Rate (DCR): The percentage of patients who achieve complete response, partial response, or stable disease.
  • Overall Survival (OS): The length of time from the start of treatment or diagnosis that patients are still alive.
  • Pharmacokinetics: The study of how a drug moves through the body, including its absorption, distribution, metabolism, and excretion.
  • Dose-Limiting Toxicity: Side effects of a drug that are severe enough to prevent an increase in dosage or require a reduction in dosage.
  • Expanded Access Program: A program that allows patients with serious diseases to access investigational drugs outside of clinical trials.
  • RECIST criteria: Response Evaluation Criteria in Solid Tumors, a set of rules used to assess cancer patients' response to treatment.

References

  1. https://clinicaltrials.eu/trial/study-comparing-ripretinib-and-sunitinib-for-patients-with-advanced-gastrointestinal-stromal-tumors-previously-treated-with-imatinib/
  2. https://clinicaltrials.gov/study/NCT04633122
  3. https://clinicaltrials.gov/study/NCT06619275
  4. https://clinicaltrials.eu/trial/study-of-ripretinib-vs-sunitinib-for-patients-with-advanced-gastrointestinal-stromal-tumor-with-specific-kit-exon-mutations-previously-treated-with-imatinib/
  5. https://clinicaltrials.gov/study/NCT04148092
  6. https://clinicaltrials.gov/study/NCT05080621
  7. https://clinicaltrials.gov/study/NCT04530981
  8. https://clinicaltrials.gov/study/NCT05697107